PRECISELY Targeted Therapies for patients with cancer
With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
We design innovative small molecules that precisely inhibit clinically proven kinase targets to solve for the dual challenges of resistance and selectivity.
We partner with physician-scientists to identify patient needs and the limitations of existing therapies.
We are passionate about using our expertise to address the needs of patients with cancer.





















Tangpeerachaikul, PhD

Tangpeerachaikul, PhD
Portfolio Management

Portfolio Management
Development

Development






Analysis

Analysis
























Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Read More >Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors
Read More >Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results
Read More >